Swiss National Bank Portfolio holdings
The Swiss National Bank (SNB), founded in 1907 and headquartered in Zurich with an office in Bern, is Switzerland’s central bank, responsible for conducting monetary policy, issuing the Swiss franc, and ensuring price stability, while uniquely managing a massive investment portfolio. Unlike most central banks, the SNB is a joint-stock company with shares traded on the SIX Swiss Exchange, owned roughly 55% by public entities like cantons and 45% by private investors, yet it operates independently under federal oversight. It holds over $800 billion in foreign currency reserves as of late 2024—invested in global equities, bonds, and gold—to manage the franc’s value, famously intervening in markets to prevent excessive appreciation, as seen with the 2015 abandonment of the euro peg. Led by Chairman Thomas Jordan until his planned exit in September 2024, the SNB balances its dual role as a monetary authority and a significant global investor, influencing both Swiss and international financial stability.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$133M |
| 2 |
AbbVie
ABBV
|
+$110M |
| 3 |
Regeneron Pharmaceuticals
REGN
|
+$93.9M |
| 4 |
Amazon
AMZN
|
+$91.8M |
| 5 |
Otis Worldwide
OTIS
|
+$84M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$226M |
| 2 |
RTN
Raytheon Company
RTN
|
+$145M |
| 3 |
WBC
WABCO HOLDINGS INC.
WBC
|
+$51.2M |
| 4 |
Newmont
NEM
|
+$50.7M |
| 5 |
Yum! Brands
YUM
|
+$33.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.6% |
| 2 | Healthcare | 15.16% |
| 3 | Consumer Discretionary | 12.49% |
| 4 | Communication Services | 10.41% |
| 5 | Industrials | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2001
Signet Jewelers
SIG
$3.6B
| $1.2M | ﹤0.01% |
116,800
+15,400
| +15% | +$152K |
|
2002
Stoneridge
SRI
$201M
| $1.2M | ﹤0.01% |
58,100
+5,000
| +9% | +$93.7K |
|
2003
BioXcel Therapeutics
BTAI
$34.9M
| $1.2M | ﹤0.01% |
+1,413
| New | +$921K |
|
2004
Children's Place
PLCE
$53.4M
| $1.2M | ﹤0.01% |
32,000
+1,800
| +6% | +$61.2K |
|
2005
Kelly Services Class A
KELYA
$566M
| $1.2M | ﹤0.01% |
75,600
+13,300
| +21% | +$190K |
|
2006
Relmada Therapeutics
RLMD
$507M
| $1.19M | ﹤0.01% |
+26,600
| New | +$1.12M |
|
|
NVEE
2007
DELISTED
NV5 Global
NVEE
| $1.19M | ﹤0.01% |
93,600
+14,000
| +18% | +$158K |
|
2008
Phibro Animal Health
PAHC
$1.38B
| $1.19M | ﹤0.01% |
45,200
+5,900
| +15% | +$147K |
|
2009
CEL-SCI Corp
CVM
$26M
| $1.19M | ﹤0.01% |
+2,647
| New | +$1.09M |
|
2010
MYR Group
MYRG
$5.1B
| $1.18M | ﹤0.01% |
37,100
+4,800
| +15% | +$131K |
|
2011
Adtran
ADTN
$658M
| $1.18M | ﹤0.01% |
108,100
+16,600
| +18% | +$171K |
|
|
PAE
2012
DELISTED
PAE Incorporated Class A Common Stock
PAE
| $1.18M | ﹤0.01% |
+123,300
| New | +$1.1M |
|
2013
Collegium Pharmaceutical
COLL
$913M
| $1.18M | ﹤0.01% |
67,300
+15,300
| +29% | +$300K |
|
2014
Gorman-Rupp
GRC
$2.11B
| $1.18M | ﹤0.01% |
37,847
+2,400
| +7% | +$70.3K |
|
2015
Krystal Biotech
KRYS
$9.72B
| $1.18M | ﹤0.01% |
28,400
+6,600
| +30% | +$318K |
|
2016
MBIA
MBI
$262M
| $1.18M | ﹤0.01% |
162,200
+14,700
| +10% | +$107K |
|
|
IGMS
2017
DELISTED
IGM Biosciences
IGMS
| $1.18M | ﹤0.01% |
+16,100
| New | +$978K |
|
|
SHYF
2018
DELISTED
The Shyft Group
SHYF
| $1.18M | ﹤0.01% |
69,800
+5,600
| +9% | +$84.6K |
|
|
CMO
2019
DELISTED
Capstead Mortgage Corp.
CMO
| $1.17M | ﹤0.01% |
213,900
+30,400
| +17% | +$153K |
|
|
KREF
2020
KKR Real Estate Finance Trust
KREF
$502M
| $1.17M | ﹤0.01% |
70,600
+20,400
| +41% | +$323K |
|
2021
Camden National
CAC
$996M
| $1.17M | ﹤0.01% |
33,861
+4,400
| +15% | +$139K |
|
2022
Community Trust Bancorp
CTBI
$1.44B
| $1.17M | ﹤0.01% |
35,690
+4,600
| +15% | +$148K |
|
2023
Nicolet Bankshares
NIC
$3.73B
| $1.17M | ﹤0.01% |
21,300
+3,900
| +22% | +$210K |
|
2024
Cue Biopharma
CUE
$131M
| $1.16M | ﹤0.01% |
+1,580
| New | +$1.14M |
|
|
MIK
2025
DELISTED
Michaels Stores, Inc
MIK
| $1.16M | ﹤0.01% |
163,843
-17,900
| -10% | -$70.2K |
|
Similar funds
Swiss National Bank's Q2 2020 Portfolio in Review
As of Q2 2020, Swiss National Bank held 2,599 positions worth $118B, up 26% from $94.2B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Swiss National Bank's Q2 2020 filing shows 119 new, 2,134 increased, 181 reduced and 161 closed positions. Its largest new stake was Otis Worldwide: 1,621,054 shares worth $92.2M. The largest sale was Allergan plc, an estimated $226M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Swiss National Bank's largest Q2 2020 buy was Otis Worldwide: 1,621,054 shares worth $92.2M.
- Swiss National Bank added most to Alibaba in Q2 2020, an estimated $133M increase.
- Swiss National Bank's biggest Q2 2020 reduction was Newmont, cutting an estimated $50.7M.
- Swiss National Bank fully exited Allergan plc in Q2 2020, selling an estimated $226M.
- Swiss National Bank's ten largest holdings make up 24% of its $118B portfolio in Q2 2020.
- Swiss National Bank opened 119 new positions and closed 161 in Q2 2020.
- Swiss National Bank's portfolio value rose 26% quarter-over-quarter to $118B.
Based on Swiss National Bank's 13F filing for Q2 2020, filed 5 Aug 2020.